We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+5.69%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$1.68B
AUM Growth
-$109M
Cap. Flow
-$70.1M
Cap. Flow %
-4.17%
Top 10 Hldgs %
48.34%
Holding
155
New
26
Increased
23
Reduced
13
Closed
37

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$26.4M
2
VTYX
Ventyx Biosciences
VTYX
+$20.8M
3
CBIO
Crescent Biopharma
CBIO
+$19.3M
4
APLS
Apellis Pharmaceuticals
APLS
+$18.3M
5
VRDN icon
Viridian Therapeutics
VRDN
+$16.2M

Top Sells

Rank Stock Value
1
BLU
BELLUS Health Inc.
BLU
+$30.4M
2
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$28.4M
3
ONC
BeOne Medicines Ltd
ONC
+$23.7M
4
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$21.4M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$13.3M

Sector Composition

Rank Sector Weight
1 Healthcare 93.97%
2 Consumer Discretionary 5.18%
3 Financials 0.37%
4 Real Estate 0.31%
5 Technology 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRBU icon
101
Caribou Biosciences
CRBU
$146M
$559K 0.03%
105,347
– –
INKT icon
102
MiNK Therapeutics
INKT
$51.7M
$549K 0.03%
28,959
– –
MTCR
103
DELISTED
Metacrine, Inc. Common Stock
MTCR
$528K 0.03%
924,898
– –
ARVN icon
104
Arvinas
ARVN
$530M
$495K 0.03%
+18,108
New +$572K
CRVS icon
105
Corvus Pharmaceuticals
CRVS
$1.1B
$455K 0.03%
500,000
– –
HIPO icon
106
Hippo Holdings
HIPO
$777M
$390K 0.02%
24,000
– –
BEAM icon
107
Beam Therapeutics
BEAM
$2.68B
$336K 0.02%
+10,975
New +$433K
LVTX
108
DELISTED
LAVA Therapeutics
LVTX
$332K 0.02%
200,000
– –
KRTX
109
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$317K 0.02%
1,747
-148,253
-99% -$28.4M
BAC icon
110
Bank of America
BAC
$429B
$229K 0.01%
+8,000
New +$264K
AIG icon
111
American International
AIG
$42.5B
$201K 0.01%
+4,000
New +$234K
CFG icon
112
Citizens Financial Group
CFG
$30.1B
$152K 0.01%
+5,000
New +$196K
PRTA icon
113
Prothena Corp
PRTA
$448M
$133K 0.01%
+2,746
New +$145K
DICE
114
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$124K 0.01%
+4,318
New +$128K
KA
115
DELISTED
Kineta, Inc. Common Stock
KA
$103K 0.01%
31,055
– –
SNTI icon
116
Senti Biosciences Holdings
SNTI
$10.8M
$66K ﹤0.01%
5,556
– –
RUBY
117
DELISTED
Rubius Therapeutics, Inc
RUBY
$44K ﹤0.01%
2,042,666
– –
CFRX
118
DELISTED
ContraFect Corporation
CFRX
$34K ﹤0.01%
18,750
– –
ACIU icon
119
AC Immune
ACIU
$231M
– –
-1,000,000
Closed -$2.04M
APLT
120
DELISTED
Applied Therapeutics
APLT
– –
-400,000
Closed -$304K
AURA icon
121
Aura Biosciences
AURA
$725M
– –
-410,000
Closed -$4.3M
BEKE icon
122
CALL
KE Holdings
BEKE
$17.7B
– –
-800,000
Closed -$11.2M
BHVN icon
123
Biohaven
BHVN
$2.02B
– –
-500,000
Closed -$6.94M
CDTX
124
DELISTED
Cidara Therapeutics
CDTX
– –
-11,234
Closed -$170K
CRDF icon
125
Cardiff Oncology
CRDF
$63M
– –
-750,000
Closed -$1.05M
3 4
5
6 7

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q1 2023 Portfolio in Review

As of Q1 2023, Artal Group held 155 positions worth $1.68B, down 6.1% from $1.79B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Artal Group withdrew a net $70.1M in Q1 2023, closing 37 positions and reducing 13 holdings. Its most notable exit was BELLUS Health Inc., an estimated $30.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 92% a quarter earlier, followed by Consumer Discretionary and Financials.

Against the trend, Artal Group opened a new position in Ventyx Biosciences worth $17.9M.

  • Artal Group's largest Q1 2023 buy was Ventyx Biosciences: 535,812 shares worth $17.9M.
  • Artal Group added most to Revolution Medicines in Q1 2023, an estimated $26.4M increase.
  • Artal Group's biggest Q1 2023 reduction was Karuna Therapeutics, Inc. Common Stock, cutting an estimated $28.4M.
  • Artal Group fully exited BELLUS Health Inc. in Q1 2023, selling an estimated $30.4M.
  • Artal Group's ten largest holdings make up 48% of its $1.68B portfolio in Q1 2023.
  • Artal Group opened 26 new positions and closed 37 in Q1 2023.
  • Artal Group's portfolio value fell 6.1% quarter-over-quarter to $1.68B.

Based on Artal Group's 13F filing for Q1 2023, filed 12 May 2023.